Andrea S. Fung

610 University Avenue, M5G 2 M9
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Risk Factors for Catastrophic Health Events in Head and Neck Cancer: A Scoping Review to Inform Risk Prediction.

Risk Factors for Catastrophic Health Events in Head and Neck Cancer: A Scoping Review to Inform Risk Prediction.

Journal: Cancers

Published: May 04, 2026

Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].

Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 17, 2025

Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.

Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.

Journal: Immunotherapy

Published: November 01, 2025

Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.

Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.

Journal: Cancers

Published: June 11, 2025

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE).

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 17, 2025

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.

Journal: Immunotherapy

Published: April 04, 2025

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 22, 2024

Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center.

Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center.

Journal: JTO clinical and research reports

Published: January 23, 2024

An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.

An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.

Journal: Immunotherapy

Published: July 11, 2023

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.

Journal: JTO clinical and research reports

Published: June 30, 2023

Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.

Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.

Journal: Cancer treatment and research communications

Published: March 27, 2023

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.

Journal: Nature medicine

Published: March 14, 2023

Showing 1-12 of 34

Last Updated: 09/26/2026